 Your new post is loading...
 Your new post is loading...
|
Scooped by
Gilbert C FAURE
April 9, 2019 2:38 PM
|
|
Scooped by
Gilbert C FAURE
April 9, 2019 3:16 AM
|
|
Scooped by
Gilbert C FAURE
April 8, 2019 2:30 AM
|
Journal of Immunology Research is a peer-reviewed, Open Access journal that provides a platform for scientists and clinicians working in different areas of immunology and therapy. The journal publishes research articles, review articles, as well as clinical studies related to classical immunology,...
|
Scooped by
Gilbert C FAURE
April 7, 2019 2:18 PM
|
Overt polyautoimmunity (PolyA) corresponds to the presence of more than one well-defined autoimmune disease (AD) manifested clinically in a single pat…
|
Scooped by
Gilbert C FAURE
April 6, 2019 2:34 PM
|
The introduction of the anti-phosphatidylserine/prothrombin (aPS/PT) antibodies among the routinely investigated anti-phospholipid (aPL) antibodies led to an improvement in anti-phospholipid syndrome (APS) laboratory diagnostic performance; however, their pathogenic mechanism is still substantially undefined. To support clinical data and future inclusion as possible new criteria antibodies, we designed a head-to-head study to directly compare the procoagulant effects sustained in vitro by aPS/PT to those sustained by anti-β2-glycoprotein I (aβ2GpI) domain 1-specific antibodies. Blood donors-derived monocytes and endothelial cells (HUVEC) were stimulated with lipopolysaccharides (LPS) alone or in combination with the IgG fractions isolated from the serum of six APS patients, positive only for aβ2GpI or for aPS/PT antibodies. As control, cells were incubated with LPS plus the IgG isolated from blood donors. Tissue factor (TF) mRNA expression was measured after four hours incubation by real-time PCR. Nitric oxide (NO) levels were measured in cells supernatant after 16 h incubation by colorimetric assay. aPS/PT and aβ2GpI IgG antibodies fractions showed comparable ability to enhance LPS-induced TF mRNA expression, either in monocytes and in HUVEC. Compared to LPS alone, we found that NO levels are strongly overproduced in HUVEC treated with LPS plus aβ2GpI and aPS/PT IgG fractions. Our data support the significant and independent role of aPS/PT in the pathogenesis of the thrombotic events in APS patients, possibly adding new light to the therapeutic management of cases characterized by the sole presence of aPS/PT IgG antibodies.
|
Scooped by
Gilbert C FAURE
April 5, 2019 6:30 AM
|
Mass cytometry identifies a unique phenotype enriched in CD4+ T cells isolated from autoimmune disease patients.
|
Scooped by
Gilbert C FAURE
April 5, 2019 2:51 AM
|
From a 1-year survival of less than 50% before the discovery of glucocorticoids to over 90% at 10 years in most dedicated centres, the spectrum of SLE has profoundly evolved. Despite this improvement, several major challenges currently remain. The aim of this review is to analyse what are, according to us, the 10 most important contemporary challenges in the management of SLE. Among those are the need to treat to target to favour disease remission (or low disease activity), limit the use of glucocorticoids, derive more comprehensive tools for the evaluation of disease activity, develop more effective drugs (yielding successful trials), dissect the heterogeneity of the disease both at the molecular and genetic levels, identify relevant biomarkers for individualised treatment, manage fertility and pregnancy, tackle comorbidities such as cardiovascular risk, the prevention of infections and osteoporosis, improve the network of care (from the patients’ perspective), and favour a holistic approach (integrating fatigue, adherence to treatment, physical activity). Altogether, these 10 contemporary challenges in SLE may be considered as a roadmap for those involved in the daily care of patients with SLE, as well as for researchers who may wish to contribute to an improved management of this rare and complex disease.
|
Scooped by
Gilbert C FAURE
April 2, 2019 9:33 AM
|
The Research Report on Antinuclear Antibody Test Market provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the ANA testing market, along with revenue estimates & forecast and market share analysis. Major Insights Covered in research Study: It provides valuable information on the products, techniques, and diseases in the ANA testing market. Details on regional markets for these segments are also presented in this report. Also, leading players are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this Antinuclear Antibody Test Market. Download PDF Brochure (Antinuclear Antibody Test Market): https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=218189007 Market Segment by Diseases for Antinuclear Antibody Test Market; Rheumatoid Arthritis Systemic Lupus Erythematosus Sjögren’s Syndrome Scleroderma Other Diseases Market Segment by Techniques for Antinuclear Antibody Test Market; Based on techniques, the Antinuclear Antibody Test Market is segmented into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. The ELISA segment is expected to account for the largest share of this market due to the expanding applications of ANA in autoimmune disease testing and therapeutic drug level monitoring. Speak to Our Subject Expert:https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=218189007 Geographical Growth Insights for Antinuclear Antibody Test Market; North America is the largest regional segment in the ANA testing market, followed by Europe, Asia, and the Rest of the World (RoW). Growth in the North American market is primarily driven by the high incidence of autoimmune diseases, growing population and healthcare spending, and growth in the number of individuals covered under medical insurance in the U.S. Major Key Players Impacting the Global Market for Antinuclear Antibody Test; The major players in the antinuclear antibody test market are Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.). Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=218189007 Thermo Fisher Scientific was the leading player in the global ANA testing market. The company has a strong presence in North America, Europe, Asia, and Latin America. It focuses on expanding its presence in the ANA testing market by strategically investing in research and development activities, which enables it to launch new products in the Antinuclear Antibody Test Market. Tags:Antinuclear Antibody Test · Antinuclear Antibody Test industry · Antinuclear Antibody Test industry Analysis · Antinuclear Antibody Test Market · Antinuclear Antibody Test Market forecast · Antinuclear Antibody Test Market growth · Antinuclear Antibody Test Market key players · Antinuclear Antibody Test Market Research · Antinuclear Antibody Test Market Share · Antinuclear Antibody Test Market size · Antinuclear Antibody Test SALES
|
Scooped by
Gilbert C FAURE
March 31, 2019 7:27 AM
|
Diagnosis of autoimmune disorders in veterinary medicine...
|
Suggested by
LIGHTING
March 30, 2019 3:02 PM
|
AbstractObjective. Fatigue is reported in up to 90% of patients with SLE. This study was conducted to identify the determinants associated with fatigue in a la
|
Suggested by
Société Francaise d'Immunologie
March 29, 2019 2:17 PM
|
|
Scooped by
Gilbert C FAURE
March 19, 2019 10:26 AM
|
Systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS) are frequently discussed together and perceived as two closely related diseases (1). Indeed, up to 40% of SLE patients test positive for phospholipid antibodies (aPL) and a significant proportion of patients with primary APS (i.e. with no associated SLE or other autoimmune diseases) have circulating antinuclear (ANA) and dsDNA/chromatin antibodies (2). Patients with primary APS and SLE share lupus susceptibility genes, yet patients with primary APS do not develop complete SLE even after ten years of follow-up suggesting a more complex link between the two entities. (2-4). Indeed, SLE and APS are distinct entities within the spectrum of systemic autoimmune diseases.In this collection five manuscripts (5-9) report pathogenic pathways which appear to operate primarily in patients with SLE. The discussed mechanisms (macrophage differentiation via LXR, association of DNA methylation with SLE triggering and clinical manifestations, IFN-Inducible Protein 16 as an inflammasome regulator in lupus pathogenesis, endonucleotidase in lupus autoimmunity and vascular damage, up-regulation of TLR7-mediated IFN production) suggest that multiple heterogeneous pathways operate preferentially in patients with SLE rather than in patients with primary APS. For example, the clinical and histological characteristics of renal involvement in patients with APS definitely differentiate the two entities. In particular,
|
Rescooped by
Gilbert C FAURE
from Immunology and Biotherapies
March 19, 2019 4:49 AM
|
A new form of insulin-dependent diabetes has been recognised, occurring in patients with cancers who are treated with checkpoint inhibitors. Checkpoint inhibitors are monoclonal antibodies that block checkpoint molecules—such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed...
Via Krishan Maggon
|
|
Suggested by
Société Francaise d'Immunologie
April 9, 2019 2:12 PM
|
Crit Rev Immunol. 2005;25(2):75-102. Research Support, Non-U.S.Gov't; Review...
|
Suggested by
LIGHTING
April 8, 2019 2:18 PM
|
Type 1 diabetes is an autoimmune disease triggered, in part, by activation of CD4+ T cells specific for insulin-derived autoantigens. Wang et al . prepared ternary complexes of diabetogenic T cell receptors attached to ligands formed by binding of insulin B-chain peptides to mouse or human MHC class II proteins known to be associated with genetic susceptibility to diabetes. Structural and functional analyses revealed that fusion peptides featuring covalent linkage of the C terminus of an insulin B-chain peptide to specific fragments of insulin C-peptide were highly potent ligands, enabling avid binding of both mouse and human TCRs. These findings point to transpeptidation reactions in lysosomes as a potential source of superagonist chimeric insulin peptides with an important driver role in autoimmune diabetes.
In type 1 diabetes (T1D), proinsulin is a major autoantigen and the insulin B:9-23 peptide contains epitopes for CD4+ T cells in both mice and humans. This peptide requires carboxyl-terminal mutations for uniform binding in the proper position within the mouse IAg7 or human DQ8 major histocompatibility complex (MHC) class II (MHCII) peptide grooves and for strong CD4+ T cell stimulation. Here, we present crystal structures showing how these mutations control CD4+ T cell receptor (TCR) binding to these MHCII-peptide complexes. Our data reveal stricking similarities between mouse and human CD4+ TCRs in their interactions with these ligands. We also show how fusions between fragments of B:9-23 and of proinsulin C-peptide create chimeric peptides with activities as strong or stronger than the mutated insulin peptides. We propose transpeptidation in the lysosome as a mechanism that could accomplish these fusions in vivo, similar to the creation of fused peptide epitopes for MHCI presentation shown to occur by transpeptidation in the proteasome. Were this mechanism limited to the pancreas and absent in the thymus, it could provide an explanation for how diabetogenic T cells escape negative selection during development but find their modified target antigens in the pancreas to cause T1D.
|
Suggested by
LIGHTING
April 7, 2019 2:25 PM
|
Autoimmunity Courses, Autoimmunity Online Courses, Abul Abbas, Course on Basic and Translational Immunology, Basic Autoimmunity, Autoimmunity E-Academy
|
Scooped by
Gilbert C FAURE
April 7, 2019 2:14 PM
|
Currently, Systemic Lupus Erythematosus (SLE) therapies range from antimalarials to glucocorticoids, in addition to immunosupressive agents or biologi…
|
Suggested by
Société Francaise d'Immunologie
April 5, 2019 2:08 PM
|
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease whose pathogenesis can be conceptualized by a model based on a central role for immune complexes (ICs) between antinuclear antibodies and nucleic acids.
Overview April 15 - 16, 2019 Masur Auditorium, NIH 10 Center Dr. Building 10 NIH Bethesda, MD 20814 This meeting will focus on two issues and will include speakers from the NIH intramural and extramural communities: 1) Understanding the biology of immune-related adverse events which have occurred in cancer patients being treated with immunotherapies and how that might inform the study of autoimmune disease. 2) Defining the potential for the study of autoimmune disease to lead to greater understanding of the treatment and management of immune-related adverse events during and following cancer therapies. “Artwork courtesy of Colleen Curran” Organizing Committee Cancer-Autoimmunity Katarzyna Bourcier, PhD, Program Officer, National Institute of Allergy and Infectious Diseases Elizabeth Jaffee, MD, AACR President, Deputy Director, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University Marie Mancini, PhD, Program Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases Elad Sharon, MD, Co-Chair, Cancer Moonshot Adult Immunotherapy Implementation Team, National Cancer Institute Connie Sommers, PhD, Program Director, National Cancer Institute Howard Young, PhD, Principal Investigator, National Cancer Institute “Dedicated to the Career and Memory of Dr. Stephen Katz” “Continuing Medical Education Activity – AMA PRA Category 1 Credits™ available!” Registration REGISTER NOW!
Via Krishan Maggon
|
Scooped by
Gilbert C FAURE
April 2, 2019 1:47 PM
|
J Intern Med. 2019 Mar 20. doi: 10.1111/joim.12888.[Epub ahead of print]...
|
Scooped by
Gilbert C FAURE
April 1, 2019 8:12 AM
|
Results Data from 2970 patients from Latin America and 18019 patients from Europe, North America and Asia were analyzed. Colombian patients have a lower age at disease onset than those from other Latin American countries and a higher rate of positivity of antinuclear antibodies and rheumatoid factor. A significant difference in the proportion of female patients in Latin America compared with Europe and North America was observed. The spectrum of disease in Latin American was similar to North American patients, while strong differences were noticed between Latin American and European and Asian patients. Noteworthy, a paucity of reports including African and African-descendent patients was observed. Conclusions The clinical spectrum of SS differs between countries and continents. Genetic differences relying upon ancestry could explain these findings. However, environmental factors have proven to be important determinants in the development of autoimmune diseases (i.e., autoimmune ecology). Thus, ancestry and the autoimmune ecology should be considered in studies aimed to evaluate the geoepidemiology of SS and other autoimmune diseases.
|
Scooped by
Gilbert C FAURE
March 31, 2019 7:26 AM
|
PeerJ. 2019 Mar 19;7:e6737. doi: 10.7717/peerj.6737. eCollection 2019.
|
Scooped by
Gilbert C FAURE
March 30, 2019 5:47 AM
|
|
Suggested by
LIGHTING
March 29, 2019 2:16 PM
|
European League Against Rheumatism and are jointly supporting multiphase development of systemic lupus erythematosus (SLE) classification criteria based on weighted criteria and a continuous probability scale. Prior steps included item generation, item reduction and hierarchical organisation of candidate criteria using an evidence-based approach. Our objectives were to determine relative weights using multicriteria decision analysis (MCDA) and to set a provisional threshold score for SLE classification. An SLE Expert Panel (8 European, 9 North American) submitted 164 real, unique cases with a wide range of SLE probability in a standardised format. Using the candidate criteria, experts scored and rank-ordered 20 representative cases. At an in-person meeting, experts reviewed inter-rater reliability of scoring, further refined criteria definitions and participated in an MCDA exercise. Based on expert consensus decisions on pairwise comparisons of criteria, 1000minds software calculated criteria weights and rank-ordered the remaining 144 cases based on their additive scores. The score of the lowest-ranked case for which complete expert consensus was achieved defined the provisional threshold classification score. Inter-rater reliability of scoring cases with the candidate criteria was good. MCDA involved 74 pairwise decisions and was repeated for the arthritis and mucocutaneous domains when the initial ranking of some cases did not match expert opinion. After criteria weights and additive scores were recalculated once, experts reached consensus for SLE classification for all cases scoring>83. Using an iterative process, the candidate criteria definitions were refined, preliminary weights were calculated and a provisional threshold score for SLE classification was determined.
The treatment of Lupus Nephritis (LN) is an unmet need in the management of patients with Systemic Lupus Erythematosus (SLE). We report two cases of women affected by Lupus Nephritis (LN) ISN/RNP Class IV with serological active disease, high disease activity and marked fatigue. In both cases, Mycophenolate mofetil (MMF), as induction therapy, was poorly tolerated because of gastrointestinal toxicity. Belimumab, together with low-doses of MMF, was effective as induction treatment leading to early achievement of complete renal response in these two selected cases of LN. We also report a literature review concerning the efficacy and safety of Belimumab in Lupus Nephritis. Further studies are needed to evaluate the use of Belimumab to manage the renal involvement in patients with Systemic Lupus Erythematosus, waiting for the results of ongoing randomized clinical trials.
Via Krishan Maggon
|